Securisyn Medical

Patented-Interlocking Tech for Medical Devices

Join CrowdabilityIQ to access our premium risk and value analysis for this deal.

Company Information



Medical Devices & Equipment


Highlands Ranch, CO

Securisyn Medical is an emerging medical-device company.

It’s received four-million dollars in funding from the U.S. Air Force and National Institutes of Health (NIH). And it has co-development partnerships with top hospitals including Mayo Clinic and the Children’s Hospital Los Angeles.

The company has thirteen issued or pending patents and has received awards from the Air Force and Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Furthermore, it’s partnered with SunMed, a leader in medical-device manufacturing, and it’s completed four Air Force contracts totaling nearly two-million dollars for the development of its technology.

So, what’s this company working on? It’s solving a multi-billion-dollar problem in the emergency-medical care sector.

In this sector, practitioners are stuck. If they need to secure a patient’s life-sustaining breathing tube, they only have two options: standard tape (time-consuming and often fails) or tube holders, which don’t hold up in real-world environments.

Every year, there are 120,000 instances of unplanned extubation, which occurs when a patient or external force pulls an inadequately-stabilized breathing tube out of the airway. At a cost of $41,000 per event, this amounts to five-billion dollars in additional healthcare costs.

Healthcare needs a device that can properly secure and optimally position breathing tubes to avoid complications.

Meanwhile, breathing tubes aren’t the only devices that slip. Medical tubes and catheters do, too. And re-inserting a tube that’s fallen out can lead to infection, tissue damage, and even death. Chest tubes are commonly secured with suture and tape, or a medical dressing. Neither is a viable solution.

Securisyn Medical has created a line of medical devices all featuring patented-interlocking technology. This technology is called Interlock, and it’s designed with a unique ribbed interface that bonds to commercially-available breathing tubes. The result is unrivaled securement that outperforms tape and other leading commercial devices.

Securisyn Medical’s first product is the SolidAIRity Flex, developed in 2021. It’s a flexible, tube-like device designed to provide unmatched airway stability for ventilated patients. The company released this product on a limited basis in Q4 2021 and is preparing for a pre-commercial launch by the end of 2022.

Additionally, Securisyn Medical partnered with the U.S. Air Force to develop a rugged breathing tube that’s battlefield-ready. The result is the SolidAIRity Frontline. The company has spent 2022 developing this device and will test and release it in 2023.

Finally, the company has created Sentry CT, a dual-use chest tube securement system which enables the prevention, management, and treatment of a collapsed lung. This vented chest seal acts as a one-way valve to allow air to exit the chest while preventing it from re-entering. Securisyn will develop this device in 2023 and aim for a commercial launch in 2024.

Initially, Securisyn Medical will target large hospital systems and military-research organizations. It will then assess user feedback prior to a nationwide launch.

Future devices include SolidAIRity Pediatric (a securement device for kids) and SolidAIRity NICU (a securement device for babies). The company and its clinical partners were recently awarded a two-million-dollar NIH Innovation Research grant to complete these devices.

Longer-term, Securisyn Medical aims to use its technology to enhance feeding tubes, catheters, and veterinary tubes.

Team Background

Arthur Kanowitz - Co-Founder & Chairman

Arthur is an emergency physician who’s spent the last sixteen years of his forty-seven-year career in emergency medicine working to improve patient safety during airway management.

In addition to his role with Securisyn Medical, he is the chair of the Patient Safety Movement Foundation’s Airway Safety Workgroup, the Founder of the Airway Safety Movement, and is the co-chair of the Society for Airway Management’s Coalition for Unplanned Extubation Awareness and Prevention. He’s also on the Board of Advisors for the Patient Safety Movement Foundation.

Arthur retired from clinical practice in emergency medicine in 2008, when he was appointed by then-Colorado Governor John Hickenlooper to serve as the Emergency Medical and Trauma Services Medical Director for the State of Colorado.

He earned his MD from the University of Colorado School of Medicine.

Mark Bruning - President & CEO

Mark has held numerous healthcare-leadership roles, most recently leading a private-equity-owned pediatric-home-healthcare company to a successful exit.

Previously, he was President of American Medical Response, the nation’s largest ambulance provider.

He holds an MBA from Northwestern University.

Elyse Blazevich - Co-Founder & Manager

Elyse guided Securisyn Medical for ten years, starting with its inception. She led the company from concept to commercialization and secured more than fifteen-million dollars’ worth of private capital, as well as four-million dollars of federal- and state-grant funding.

Currently, she is President and CEO of the Colorado Bioscience Association, which aims to assist companies in the state with health-related innovations.

She earned a Bachelor’s degree in Biology from Colorado College and a Master’s degree in Organizational Leadership from Colorado State University.


National Institutes of Health

An agency of the U.S. Department of Health and Human Services, the NIH is the primary agency of the United States government responsible for biomedical and health-related research. The NIH both conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

$5 million
$47K (1%)
Current Valuation
$40 million Cap / 20% Discount
Min. Investment
Deal Type
Title III
(For all investors)
Offering Type
Finance History
  • $2.25 million
    (Convertible Note)
  • $3.10 million
    (Preferred Interests)
Notable Investors
  • National Institutes of Health
Learn more on Republic